Eli Lilly, an American pharmaceutical company headquartered in Indianapolis, agreed to acquire Morphic, a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, for $3.2bn. "Morphic has always believed that the immense potential of MORF-057 to benefit patients suffering from IBD could be optimized by the ideal strategic partner. Lilly brings unparalleled resources and commitment to the inflammation and immunology field," Praveen Tipirneni, Morphic CEO.